On the stock market since 2025, it operates in the world of health and science. It has 49 employees. Now — the numbers.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Nothing in the current numbers stands out as a strong positive. That, by itself, is worth knowing.
The price action doesn’t yet back an upward turn. Council score: 0/10.
The sales tempo runs behind the sector. Council score: 4/10.
On our five-subject report card, MCTA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: MCTA is a high-risk stock — not yet profitable, and its future rides on its product catching on.